Tampere University Hospital to become first clinic in the world using RayPilot® for hypofractionation
RayPilot® is an electromagnetic real-time tumor tracking system that is installed on a Varian TrueBeam™ linear accelerator at the Tampere University Hospital in Finland.
The system has been used since a couple of months and the first patients are now treated. Within the first year around 80 prostate cancer patients will be treated with different protocols from normal 39 fractions to hypofractionated protocols of 5 fractions. The goal for the hospital is to shorten the overall treatment time with maintained or enhanced results for the patients.
– Real-time prostate localisation is essential when reducing the CTV to PTV margins in order to spare the healthy surrounding tissue says medical physicist Antti Vanhanen who is responsible for the RayPilot use at Tampere University Hospital.
The Tampere University Hospital is also the first clinic that has started to do RayPilot transmitter implantation under local anaesthesia.
– It is great to work with Antti Vanhanen and his colleagues at Tampere University Hospital, they are very serious and has a clear view on what they want to achieve with the RayPilot system says Hanna Syrén, Application Manager at Micropos Medical.
Micropos RayPilot® installed on a Varian TrueBeam™ at the Tampere University Hospital
For further information contact:
Tomas Gustafsson, CEO, Micropos Medical AB (publ), +46-31-772 80 99
About Micropos Medical AB (publ):
Micropos Medical AB (publ) (www.micropos.se) is a Swedish company that has developed the RayPilot® system, which is an electromagnetic positioning and real time tracking system for a fast and objective set-up and for continuous positioning during radiotherapy. A precise and safe localization of the tumor can dramatically improve the outcome of the treatment, particularly for hypofractionated protocols. The RayPilot® system consists mainly of three parts; one transmitter that is placed close by the tumor, a receiving system that is placed directly on the treatment couchtop and software that continuously shows the precise tumor location, and hence where to focus the linac beam. RayPilot® has a unique gating solution qualified and compatible for use with Varian’s Clinac® iX linear accelerators and Trilogy® systems. During 2015 Micropos will release an upcoming RayPilot® transmitter for positioning, in-situ dosimetry and automatic patient identification. RayPilot® is CE certified for prostate use. Follow us on Facebook, http://www.facebook.com/MicroposMedical. The Micropos share is traded under the stock ticker MPOS.